PAREXEL Renames Perceptive Informatics Subsidiary
PAREXEL announced a group of initiatives that include a re-designed corporate website
PAREXEL announced a group of initiatives that include a re-designed corporate website, a global marketing and advertising campaign and the rebranding of its technology subsidiary Perceptive Informatics to PAREXEL informatics.
According to the company's press release, the PAREXEL Informatics branding is in response to sponsors seeking multiple solutions from a single service provider. Said Mark A. Goldberg, President and Chief Operating Officer, PAREXEL in that release, "We are more closely integrating our clinical research and technology offerings to meet this need. Toward that end, the new PAREXEL Informatics branding communicates our commitment to providing technology-driven solutions that complement our other clinical trial services, without changing our overall go-to-market strategy."
PAREXEL will maintain the Perceptive brands to identify specific PAREXEL Informatics offerings that have market recognition that has been built over the years. These include Perceptive MyTrials eClinical platform, the Perceptive Partner Program and the Perceptive Institute.
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
